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Abstract
Context—Women with a personal history of breast cancer (PHBC) are at risk of developing
another breast cancer and are recommended for screening mammography. Few high-quality data
exist on screening performance in PHBC women.
Objective—To examine the accuracy and outcomes of mammography screening in PHBC
women relative to screening of similar women without PHBC.
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Design and Setting—Cohort of PHBC women, mammogram matched to non-PHBC women,
screened through facilities (1996–2007) affiliated with the Breast Cancer Surveillance
Consortium.
Participants—There were 58 870 screening mammograms in 19 078 women with a history of
early-stage (in situ or stage I-II invasive) breast cancer and 58 870 matched (breast density, age
group, mammography year, and registry) screening mammograms in 55 315 non-PHBC women.
Main Outcome Measures—Mammography accuracy based on final assessment, cancer
detection rate, interval cancer rate, and stage at diagnosis.
Results—Within 1 year after screening, 655 cancers were observed in PHBC women (499
invasive, 156 in situ) and 342 cancers (285 invasive, 57 in situ) in non-PHBC women. Screening
accuracy and outcomes in PHBC relative to non-PHBC women were cancer rates of 10.5 per 1000
screens (95%CI, 9.7–11.3) vs 5.8 per 1000 screens (95%CI, 5.2–6.4), cancer detection rate of 6.8
per 1000 screens (95%CI, 6.2–7.5) vs 4.4 per 1000 screens (95% CI, 3.9–5.0), interval cancer rate
of 3.6 per 1000 screens (95%CI, 3.2–4.1) vs 1.4 per 1000 screens (95% CI, 1.1–1.7), sensitivity
65.4% (95% CI, 61.5%–69.0%) vs 76.5% (95% CI, 71.7%–80.7%), specificity 98.3% (95% CI,
98.2%–98.4%) vs 99.0% (95% CI, 98.9%–99.1%), abnormal mammogram results in 2.3% (95%
CI, 2.2%–2.5%) vs 1.4% (95% CI, 1.3%–1.5%) (all comparisons P <.001). Screening sensitivity
in PHBC women was higher for detection of in situ cancer (78.7%;95% CI, 71.4%–84.5%) than
invasive cancer (61.1%; 95% CI, 56.6%–65.4%), P<.001; lower in the initial 5 years (60.2%; 95%
CI, 54.7%–65.5%) than after 5 years from first cancer (70.8%;95% CI, 65.4%–75.6%), P =.006;
and was similar for detection of ipsilateral cancer (66.3%; 95% CI, 60.3%–71.8%) and
contralateral cancer (66.1%; 95% CI, 60.9%–70.9%), P=.96. Screen-detected and interval cancers
in women with and without PHBC were predominantly early stage.
Conclusion—Mammography screening in PHBC women detects early-stage second breast
cancers but has lower sensitivity and higher interval cancer rate, despite more evaluation and
higher underlying cancer rate, relative to that in non-PHBC women.
The high prevalence of breast cancer survivors is due to general gains in life expectancy and
to improved survival in women with a personal history of breast cancer (PHBC), attributable
to improvements in local and systemic treatments and early detection. Women with PHBC
are at risk of developing second breast cancers, which can be ipsilateral (in-breast recurrence
or new ipsilateral cancer) or contralateral; risk of a second breast cancer was recently
estimated at 5.4 to 6.6 per 1000 woman years.1 The consensus is that PHBC women may
benefit from early detection of second breast cancers, although evidence of screening benefit
in these women comes from nonrandomized studies2–5 and extrapolation of benefit from
randomized population mammography screening trials. Screening or surveillance
mammography (referred to here as screening)1,6 is usually recommended by guidelines and
consensus recommendations for follow-up of PHBC women.7–12
Several reviews have concluded that little quality evidence is available on mammography
screening accuracy in PHBC women6,13,14; most studies are based on selected series, are
limited to women who had second breast cancers or further breast surgery,3,6,15–18 or use
methods that do not allow estimation of specificity.6 Studies of screening in PHBC women
predominantly report only the proportion of second cancers detected by mammography, in
the range of 10% to 80%.6,13,14 Standard measures of screening performance in PHBC
women, such as cancer detection rates or interval cancer rates for ipsilateral and
contralateral cancers, are not available from screening programs. Furthermore, interest exists
in using adjunct imaging such as higher-cost magnetic resonance imaging to screen PHBC
women19,20 despite lack of reliable data on mammography screening in these women.
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Valid estimates of the accuracy of screening mammography are therefore needed to guide
clinical practice and policy in this setting and to inform clinicians and PHBC women of
expected screening outcomes. This study examines the accuracy and outcomes of screening
mammography and factors associated with screening outcomes in women with a PHBC who
participated in mammography screening through facilities affiliated with the Breast Cancer
Surveillance Consortium (BCSC). Context on screening mammography outcomes from the
same practices in women of approximately population risk came from a comparison group
with no reported breast cancer history and with a mammogram matched to PHBC women on
breast density, age group, and mammography registry and year.
METHODS
Setting
Participants were women receiving mammograms at facilities in 5 of the 7 mammography
registries of the National Cancer Institute–funded BCSC, which collects demographic and
mammography information from women undergoing mammography at participating
community-based facilities. Each registry links data on screened women to their state or the
Surveillance, Epidemiology, and End Results cancer registries to ascertain breast cancer
diagnoses. Five registries collect both cancer registry and pathology outcomes data for
complete capture of second cancers and were sources for this study: Carolina
Mammography Registry (North Carolina), Group Health Breast Cancer Screening Project
(Washington State), New Hampshire Mammography Network, New Mexico Mammography
Project, and Vermont Breast Cancer Surveillance System. Information about the BCSC is
available at http://breastscreening.cancer.gov/.
Each registry and the BCSC Statistical Coordinating Center received institutional review
board approval for either active or passive consenting processes or a consent waiver to
enroll women, link data, and perform analytic studies. All procedures are Health Insurance
Portability and Accountability Act compliant, and all registries and the Statistical
Coordinating Center received a federal certificate of confidentiality and other protection for
identities of women, physicians, and facilities in this research.
Screening Examinations
Screening mammograms from 1996 to 2007 in PHBC women were identified. Women (44
509) with an initial early-stage breast cancer,1 including diagnoses of ductal carcinoma in
situ or American Joint Committee on Cancer21 stage I to II invasive carcinoma, were
eligible for inclusion. Cancer registry and pathology databases were used to ascertain
whether a woman had a breast cancer diagnosis, the diagnosis date, and cancer
characteristics. Excluded were women with bilateral mastectomy for first cancer. A
mammogram performed at least 6 months after first breast cancer diagnosis was defined as
screening if it was indicated as a routine screen by the radiologist or technologist, not within
9 months of a previous breast imaging examination, not a unilateral mammogram in a
woman with breast-conserving surgery, and not from a woman self-reporting a lump or
nipple discharge. Screening mammograms with at least 1 year of follow-up for ascertaining
second cancer diagnoses were included. Women meeting the inclusion criteria and receiving
at least 1 screening mammogram with a final Breast Imaging Reporting and Data System
(BI-RADS)22 assessment of 0 to 5 were eligible (eFigure, available at http://
www.jama.com).
Comparison Group
Screening examinations in non-PHBC women were matched 1:1 to screens of PHBC
women, based on Breast Imaging Reporting and Data System22 breast density, 10-year age
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group, and mammography registry and year. Screening mammograms were defined with
BCSC definitions with criteria similar to those of PHBC women (bilateral mammogram
indicated for screening in women with no reported symptoms, no mammogram in the
previous 9 months, and at least 1 year of follow-up).23
Demographic Characteristics
Age group, self-reported race/ethnicity, family breast cancer history, menopausal status,
time since last mammogram, and history of breast plastic surgery (implants, reduction, or
reconstruction) were collected at the screening.
Cancer Characteristics and Follow-up
Time since first cancer was the difference between the screening mammogram date and the
date of first breast cancer diagnosis. For first cancer, type (ductal carcinoma in situ, stage I
or II invasive), radiation therapy, adjuvant systemic therapy, and surgery (breast-conserving
surgery, mastectomy) were computed from all cancer registry records and pathology
databases that were within 6 months of initial diagnosis. For missing surgery information,
self-reported mastectomy and lumpectomy history (collected at a mammogram within 18
months after diagnosis and before a second cancer diagnosis) was used to impute primary
surgery.
In all screening participants, mammograms were considered to be associated with an
outcome of breast cancer if ductal carcinoma in situ or invasive carcinoma was observed
within 1 year of the screen.
Statistical Analysis and Measures of Accuracy
Because some mammography facilities add spot-compression magnification views to routine
screening views as a standard part of screening PHBC women, accuracy measures were
based on the final assessment at the end of imaging evaluation, using the BI-RADS22 scale.
If the initial examination assessment was BI-RADS score 0 without biopsy recommendation
or was 1, 2, or 3 with immediate follow-up recommendation, we looked for a final
assessment in imaging examinations up to 90 days after screening and before breast biopsy.
A positive final assessment result included BI-RADS assessments of 4 or 5, or 0 or 3 with
recommendation for biopsy, fine-needle aspiration, or surgical consultation.1,23,24 A
negative final assessment result included BI-RADS assessments of 1 or 2; assessment of 3
without recommendation for biopsy, fine-needle aspiration, or surgical consultation; or
assessment of 0 with normal or short-interval follow-up recommendation. Final assessment
was considered missing if the last BI-RADS assessment was 0 with recommendation for
additional imaging, unspecified evaluation, or missing recommendation (eFigure).
Accuracy measures were based on standard BCSC definitions.23 A positive mammogram
result associated with breast cancer diagnosis during follow-up (within 1 year of screen) was
defined as a true positive (or false positive if not associated with cancer diagnosis). A
negative mammogram result not associated with breast cancer during follow-up was a true
negative (or false negative if associated with cancer during follow-up). Cancer rate (number
of cancers observed during follow-up among 1000 screening mammograms), cancer
detection rate (number of true-positive results among 1000 mammograms), interval cancer
rate (number of false-negative results among 1000 mammograms), abnormal interpretation
rate (proportion of mammograms found to be positive), and positive predictive value of
biopsy recommendation (proportion of positive results associated with cancer diagnosis
during follow-up)25 were based on standard BCSC definitions.23 Accuracy analyses
excluded mastectomy-side recurrences (which would not have been examined with
mammography) in PHBC women.
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Frequency distributions of screens and cancer characteristics were computed separately for
screening mammograms in women with and without PHBC and were compared with χ2
tests. Accuracy and outcome measures and 95% confidence intervals (CIs) were computed
within cohorts and compared with score statistics obtained from generalized estimating
equation analyses. In PHBC screens, accuracy and cancer rates were examined by breast
density, time since first cancer diagnosis, type of first breast cancer, screening interval, and
treatment variables associated with first cancer. Post hoc logistic regression tested for
differences in sensitivity by systemic therapy for first cancer (none, chemotherapy,
endocrine therapy, or both), adjusting for exact age, breast density, stage and treatment of
first cancer, and mammography registry. Generalized estimating equations were used to
calculate all CIs and to fit regression models accounting for correlation in women with
multiple screening mammograms. P<.05 (2-sided) was considered statistically significant.
Analyses were performed with SAS version 9.2 (SAS Institute, Cary, North Carolina).
RESULTS
There were 58 870 screening mammograms in 19 078 women with PHBC and 58 870
matched screening examinations in 55 315 women without PHBC (TABLE 1). A higher
proportion of screening mammograms from PHBC women relative to matched non- PHBC
screens was associated with a family history of breast cancer (23.2% vs 17.6%),
postmenopausal status (91.6% vs 87.5%), history of breast plastic surgery (6.9% vs 0.8%),
and receipt of mammography between 9 and 14 months since the previous screen (82.7% vs
43.1%); all P<.001. Women with PHBC had 655 second cancers (499 invasive, 156 ductal
carcinoma in situ) and women without PHBC had 342 cancers (285 invasive, 57 ductal
carcinoma in situ) within 1 year of screening mammography. Ductal carcinoma in situ
occurred in a higher proportion of second cancers in the PHBC than in the non-PHBC group
(23.8% vs 16.7%; P=.009).
TABLE 2 reports accuracy measures and outcomes for all screening examinations. Cancer
rates were 11.1 per 1000 screens in PHBC women, or 10.5 per 1000, excluding 40
mastectomy-side recurrences that would not have been examined with mammography,
relative to 5.8 per 1000 screens in non- PHBC women. Cancer rates, cancer detection rate,
and interval cancer rate were 1.3 to 2.6 times higher for PHBC screens compared with
matched screens. PHBC screens were more frequently associated with additional imaging
(additional mammography views or ultrasonography) than matched screens (18.1% vs 8.3%;
P<.001), which was largely due to more same-day additional imaging in PHBC screens
relative to matched screens (12.4% vs 1.3%;P<.001) rather than recall for additional imaging
(7.1% vs 7.8%; P<.001). PHBC women were more likely to have a recommendation for
fine-needle aspiration, biopsy, or surgical consultation after assessment (2.2% vs 1.4%; P<.
001). Ultrasonography was performed as part of the evaluation (same day, before, or at final
assessment) of positive screening mammogram results (1874 positive screen results) less
frequently in PHBC-positive screens than in matched screens (32.3% vs 38.8%; P=.004).
Screening sensitivity in PHBC was lower (65.4%; 95% CI, 61.5%–69.0%) compared with
that in non-PHBC screens (76.5%; 95% CI, 71.7%–80.7%), P<.001. This relatively lower
screening sensitivity was largely due to lower sensitivity for detection of invasive cancer in
PHBC (61.1%; 95% CI, 56.6%–65.4%) relative to that in the matched group (75.7%; 95%
CI, 70.4%–80.3%), P<.001. In PHBC screens, cancer detection rate was higher in women
whose first cancer was ductal carcinoma in situ relative to invasive cancer (Table 2), and
this was evident for detection of both ductal carcinoma in situ and invasive second cancers.
Sensitivity was similar for detection of ipsilateral (66.3%; 95% CI, 60.3%–71.8%) and
contralateral cancer (66.1%; 95% CI, 60.9%–70.9%), P=.96; and sensitivity was higher for
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detection of ductal carcinoma in situ (78.7%; 95% CI, 71.4%–84.5%) than for invasive
cancer (61.1%; 95% CI, 56.6%–65.4%), P<.001.
Accuracy, cancer rates, cancer detection rate, and interval cancer rate in PHBC women are
reported by age, breast density, screening interval, time since first cancer diagnosis, type of
first cancer, treatment for first breast cancer, and breast plastic surgery history (TABLE 3)
(data used in the calculations are shown in eTable 1). TABLE 4 shows screening sensitivity
for these variables by second cancer laterality. Accuracy measures, cancer rates, and interval
cancer rate were associated with age, although the lower sensitivity in women younger than
50 years was more evident for contralateral cancer detection. Sensitivity and specificity
decreased and abnormal interpretation rate, cancer rates, cancer detection rate, and interval
cancer rate increased with increasing BI-RADS22 density categories. Sensitivity was 69.6%
(95% CI, 63.3%–75.3%) in less dense breasts (BIRADS category 1–2) and was higher than
the sensitivity of 60.2% (95% CI, 54.0%–66.2%) in more dense breasts (BI-RADS category
3–4), P=.03.
Specificity and positive predictive value increased, sensitivity and cancer detection rate
varied, and abnormal interpretation rate decreased with increasing time since first cancer
diagnosis (Table 3). Sensitivity in the initial 5 years from first cancer (60.2%; 95% CI,
54.7%–65.5%) was lower than sensitivity after 5 years (70.8%; 95% CI, 65.4%–75.6%), P=.
006. Cancer detection rate also differed between the initial 5 years (5.8/1000 screens; 95%
CI, 5.0–6.7) and after the initial 5 years (8.1/1000 screens; 95% CI, 7.1–9.3) from first
cancer diagnosis, P<.001, predominantly because of increased cancer detection rate for
invasive cancer between the initial 5 years (3.7/1000 screens; 95% CI, 3.1–4.4) and after the
initial 5 years (6.2/1000 screens; 95% CI, 5.3–7.2), P<.001.
Specificity and abnormal interpretation rate were associated with time since previous
mammogram (Table 3); however, most PHBC screens occurred between 9 and 14 months
after previous mammography. Sensitivity, abnormal interpretation rate, positive predictive
value, cancer rates, and cancer detection rate were higher in women with previous ductal
carcinoma in situ relative to those with previous invasive cancer (Table 3), although the
sensitivity difference was more evident for detection of ipsilateral (second) cancers (Table
4).
Specificity was higher and abnormal interpretation rate lower in women who had received
mastectomy relative to breast-conserving surgery for first cancer. Radiation therapy was
associated with a very small but significant specificity reduction and abnormal interpretation
rate increase. Cancer rates, cancer detection rate, and interval cancer rate varied between
women who had breast-conserving surgery with or without radiation or mastectomy (Table
3): the highest cancer detection and interval cancer rates were observed in women treated
with breast-conserving surgery without radiation for their first cancer. Sensitivity, abnormal
interpretation rate, and positive predictive value were higher in women who had not
received any systemic therapies, as were underlying cancer rates and cancer detection rate
(Table 3). After adjusting for age, density, stage and treatment of first cancer, and
mammography registry, women with chemotherapy were significantly less likely to have
their cancer detected by mammography (odds ratio [OR]=0.45; 95% CI, 0.22–0.94) than
women without systemic therapy. Women with endocrine therapy alone (OR=0.63; 95% CI,
0.35–1.15) or combined with chemotherapy (OR= 0.69; 95% CI, 0.29–1.67) also had lower
sensitivity than women with no therapy, but this was nonsignificant.
Sensitivity and positive predictive value were lower in screens with self-reported breast
plastic surgery history relative to no plastic surgery (lower sensitivity was more apparent
when reduction was excluded), but overall this was not significant (Table 3). The lower
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sensitivity in screens with self-reported breast plastic surgery was evident mainly for
contralateral cancer (Table 4); however, the number in this group was small.
Stage and node status for cancers occurring within 1 year of screening are in eTable 2, with
generally similar stage distributions for interval cancers in both cohorts, although invasive
interval cancers were more likely to be stage I than stage II in PHBC women compared with
non-PHBC women. Screen-detected cancers had a favorable profile in PHBC women and
matched screens, with the majority being early-stage cancers.
COMMENT
Breast cancer survivors represent an increasing group and are at risk of cancer in the
conserved and contralateral breast. To our knowledge, we report the first comprehensive
study of accuracy measures of mammography screening in PHBC women that includes both
ipsilateral and contralateral breast screening outcomes, providing evidence to inform
practice and guide recommendations on mammography screening in PHBC women.7,9,10
Key findings are that mammography screening in PHBC women detects cancers at an early
stage but has lower accuracy than screening in women without PHBC, despite a higher rate
of additional evaluation and higher underlying cancer rates in PHBC women. Our study also
shows that screening mammography in PHBC women has a relatively high interval cancer
rate, although most interval cancers in these women had favorable tumor stage profiles.
Because population mammography screening accuracy differs across screening programs
and countries, a major strength of our study is integration of matched screens from women
without PHBC, providing context on screening accuracy inmammography registries that
contributed data to this study and allowing judgment about the generalizability of our
findings. It also allows an understanding of mammography screening outcomes and how
these differ in PHBC women relative to non-PHBC women, as highlighted in Table 2.
Measures of screening accuracy should, however, be interpreted with awareness that these
calculations were based on final assessment (at completion of imaging evaluation). Our
design of matching screening mammograms for characteristics including breast density and
age group allowed us to validly compare screening accuracy between the 2 groups.
Although different numbers of women were required to achieve the necessary mammogram-
level matching, our estimates for cancer rates, cancer detection rate, and interval cancer rate
are reported per 1000 screening examinations, with follow-up set at 12 months for all
screens, allowing unbiased comparison of these rates between the 2 groups. Furthermore, the
majority of women in both groups reported having mammography before that included in
our analysis (Table 1); hence, our estimates represent predominantly incident (repeated)
screening outcomes and allow analytically for clustering in women with multiple screens.
In general, screening did not perform as well in PHBC women relative to that in women
without PHBC: sensitivity and specificity were lower for PHBC women, and screening
examinations were approximately twice as likely to be recommended for additional imaging
or biopsy. Screening positive predictive value was similar in both groups, in part because of
the higher cancer incidence in PHBC women. Cancer rates, cancer detection rate, interval
cancer rate, and the proportion of cancers that were interval cancers were significantly
higher in PHBC women, highlighting their higher underlying risk of breast cancer, as well
as their relatively lower screening sensitivity. Despite the lower sensitivity, the stage
distribution of screen-detected cancers shows that mammography is effective in detecting
early-stage second breast cancers in PHBC women because the majority were ductal
carcinoma in situ or stage I cancers. Our findings support annual mammography screening
recommendations in PHBC women7,8,10 but also highlight issues needing further evaluation.
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We report a relatively high interval cancer rate in PHBC women, even though the majority
of screens were conducted between 9 and 14 months after the previous mammogram. We
cannot compare our interval cancer rate to that of other studies because, to our knowledge,
this is the first report of interval cancer rate for screening PHBC women that factors
ascertainment of both ipsilateral and contralateral breast outcomes and a relative interval
cancer rate for matched screens in women without PHBC. One other study of population-
based screening of women with PHBC,26 based on 114 women with contralateral cancer,
reported sensitivities of 59.6% overall and 70.8% for the subgroup with annual
mammography. Screening specificity was 98.3% and the proportion of contralateral breast
cancers that were interval cancers was 34.2%26 (similar to data in Table 2); however,
interval cancer rate was not reported. Buist et al1 recently reported that about one-third of
second breast cancers in BCSC women were not screen detected. Comparison of our work
with other studies of PHBC women is not appropriate because the latter generally reports the
proportion of second cancers detected by mammography in selected series of PHBC women
and does not provide valid data on all measures of screening accuracy.6,13
We used final assessment to calculate screening accuracy rather than initial interpretation
based only on the screening mammogram because a substantial number of PHBC women
had additional imaging on the same day as the screen. We were unable to distinguish the
extent to which this represented evaluation of screen-detected abnormalities or additional
imaging performed as standard of care for PHBC women at some facilities. An absolute
estimate of screening “recall rate” that includes callback for additional imaging could
therefore not be estimated. Our “abnormal” assessment measure was based on a
recommendation for biopsy or surgical consultation, whereas studies of population breast
screening accuracy often consider recommendations for additional imaging as a positive
result. Thus, our abnormal interpretation rate, sensitivity, and specificity are not directly
comparable to the recall rate, sensitivity, and specificity usually reported in population
screening evaluations, and studies focusing on PHBC women have not reported screening
recall rates.6,13 Our study provides valid relative estimates of accuracy measures, including
a significantly higher abnormal interpretation rate and lower sensitivity and specificity in
PHBC women relative to non-PHBC women. We also found that additional imaging at
initial screening was more than twice as frequent among PHBC women, although this was
predominantly due to same-day additional imaging in PHBC women.
Screening examinations of PHBC women revealed an approximately 2-fold higher risk of
breast cancer during follow-up relative to screens of women without PHBC, matched for
age, breast density, mammography registry, and year. Underlying cancer rates were lower in
PHBC women who had mastectomy rather than breast-conserving surgery for the first
cancer and were similar to cancer rates in the matched non-PHBC cohort (Tables 2 and 3),
which is consistent with recent risk models that estimated that lifetime risk of breast cancer
in PHBC women is a function of the number of breasts at risk for developing another
cancer.20 This may also partly account for the higher specificity and lower cancer rates
found in PHBC women with mastectomy in our data. Our study shows that PHBC women
have heterogeneous risk for developing another breast cancer; thus, consideration of a more
tailored screening approach might be warranted in some PHBC women, according to our
estimates for underlying cancer rates and screening sensitivity. The highest observed cancer
rates in our PHBC cohort (>12 cancers/1000 screens, or greater than twice the cancer rates
in non-PHBC women) were in women younger than 50 years, women with extremely dense
breasts, women with previous ductal carcinoma in situ, women who received breast-
conserving surgery without radiation or did not receive any systemic therapy, and those with
inter-screening interval greater than 2 years.
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We were surprised to find higher mammography sensitivity (evident for ipsilateral and
contralateral cancer) in women who had not received systemic therapy, for whom
underlying cancer rates were also higher compared with those who received chemotherapy
or endocrine therapy. Examination of this association, after adjusting for relevant variables,
showed significantly reduced sensitivity only in women who received chemotherapy.
Because receipt of systemic therapy was based on cancer registry information, the data
might have been incomplete. Further research examining whether this finding may be due to
potential confounding by biological factors associated with first cancer treatment (for
example, hormone receptor status) would be valuable. Similarly, some of our findings
should be interpreted with consideration of possible confounding by factors associated with
the first cancer and its treatment. For example, the higher cancer rates, cancer detection rate,
and screening sensitivity in PHBC women whose first cancer was ductal carcinoma in situ
may be reflecting the effect of use of systemic therapy (usually not used for ductal
carcinoma in situ and frequently used for invasive cancer), which reduces the risk of another
breast cancer, rather than a differential biological susceptibility in women with personal
history of ductal carcinoma in situ relative to invasive cancer.
The interval cancer rate we report for PHBC women might raise concerns about whether the
potential benefit of screening is fully realized in these women. Although there is interest in
adjunct screening for PHBC women, 19,20,27 there is no evidence that this improves clinical
end points and no consensus regarding which of these women (other than those with proven
cancer gene mutations) should have adjunct imaging. Furthermore, despite a relatively high
interval cancer rate in PHBC women, interval cancers were predominantly early stage,
although the proportion of stage IIB and III cancers was slightly higher than that of non-
PHBC interval cancers. Thus, although mammography screening is less sensitive in PHBC
women, our study provides evidence that both screen-detected and interval cancers are, in
general, equally early stage among PHBC women and those without PHBC. These data
neither support nor negate a role for adjunct screening in PHBC women but suggest that
adjunct screening should be studied in women younger than 50 years, women with denser
breasts, or those who received chemotherapy for their first cancer because screening these
women had the lowest sensitivity among PHBC women. The data also raise consideration of
exploring alternate approaches, such as biomarkers, for future screening in PHBC women.
Evaluation of adjunct (or alternate) screening might be considered in PHBC subgroups in
whom unacceptably high interval cancer rates were found (for example, interval cancer rate
≥6 cancers/1000 screens), including women younger than 50 years, women with extremely
dense breasts, and those who received breast conservation without radiotherapy for their first
cancer.
Our findings on interval cancers in PHBC women raise several possibilities. First, PHBC
women may have different host factors predisposing them not only to risk of a second breast
cancer but also to breast cancers that are less likely to be detected with screening, possibly
because of more rapid growth or other tumor biology characteristics. Second, they may
partly reflect higher breast awareness by PHBC women, who might seek help promptly for
breast symptoms. Third, assuming that many interval cancers in PHBC women are
symptomatic diagnoses is reasonable, but some interval cancers may be due to adjunct
screening (magnetic resonance imaging or ultrasonography) occurring in between
mammography screenings. We did not have data to examine adjunct screening as a possible
explanation for the early-stage interval cancers in PHBC women, but guidelines for
magnetic resonance imaging screening in high-risk women were available at the end of our
study.19
This study provides evidence that screening mammography detects early-stage breast
cancers in PHBC women but has lower accuracy relative to screening women without
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PHBC. Despite a relatively high interval cancer rate, interval cancers in PHBC women had
generally favorable stage distributions. Our work also shows that screening outcomes and
breast cancer rates in PHBC women are associated with various factors, including the
treatment received for the first cancer, so these women have heterogeneous underlying risks
for a second breast cancer, and a more tailored screening strategy than currently
recommended might be warranted.
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Table 1
Characteristics of Screening Mammograms in Women With a Personal History of Breast Cancer (PHBC) and
Matched Screening Mammograms in Women Without a PHBC
No. (%)
Women (n = 19 078)
With PHBC











Within 1 Year of
Screeningb
Screening examinations, total 58 870 655 58 870 342
Age at mammography, y
   <40 727 (1.2) 14 (1.9) 727 (1.2) 0
   40–49 6104 (10.4) 98 (1.6) 6104 (10.4) 18 (0.3)
   50–59 14 532 (24.7) 165 (1.1) 14 532 (24.7) 50 (0.3)
   60–69 14 795 (25.1) 130 (0.9) 14 795 (25.1) 90 (0.6)
   70–79 15 171 (25.8) 165 (1.1) 15 171 (25.8) 113 (0.7)
   ≥80 7541 (12.8) 83 (1.1) 7541 (12.8) 71 (0.9)
BI-RADS breast density
   1, Almost entirely fatty 3448 (7.5) 18 (0.5) 3448 (7.5) 9 (0.3)
   2, Scattered fibroglandular tissue 22 155 (48.3) 224 (1.0) 22 155 (48.3) 117 (0.5)
   3, Heterogeneously dense 17 885 (39.0) 219 (1.2) 17 885 (39.0) 116 (0.6)
   4, Extremely dense 2418 (5.3) 39 (1.6) 2418 (5.3) 17 (0.7)
   Missing data 12 964 (22.0) 155 (1.2) 12 964 (22.0) 83 (0.6)
Race/ethnicity
   White, non-Hispanic 47 489 (84.2) 531 (1.1) 47 119 (83.3) 285 (0.6)
   Black, non-Hispanic 2018 (3.6) 21 (1.0) 2027 (3.6) 9 (0.4)
   Hispanic 4707 (8.3) 45 (1.0) 4783 (8.5) 14 (0.3)
   Asian/Pacific Islander 984 (1.7) 10 (1.0) 1115 (2.0) 12 (1.1)
   Other 1234 (2.2) 13 (1.1) 1496 (2.6) 8 (0.5)
   Missing data 2438 (4.1) 35 (1.4) 2330 (4.0) 14 (0.6)
Family history of breast cancer
   No 37 956 (76.8) 381 (1.0) 41 065 (82.4) 187 (0.5)
   Yes 11 459 (23.2) 169 (1.5) 8744 (17.6) 81 (0.9)
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No. (%)
Women (n = 19 078)
With PHBC











Within 1 Year of
Screeningb
   Missing data 9455 (16.1) 105 (1.1) 9061 (15.4) 74 (0.8)
Menopausal status
   Pre 3580 (6.9) 74 (2.1) 5945 (11.2) 15 (0.3)
   Peri 763 (1.5) 19 (2.5) 722 (1.4) 4 (0.6)
   Post 47 187 (91.6) 483 (1.0) 46 600 (87.5) 313 (0.7)
   Missing data 7340 (12.5) 79 (1.1) 5603 (9.5) 10 (0.2)
Time since last mammogram, mo
   No previous mammogram 106 (0.2) 4 (3.8) 1581 (2.9) 18 (1.1)
   9–14 47 872 (82.7) 511 (1.1) 23 799 (43.1) 94 (0.4)
   15–23 7358 (12.7) 84 (1.1) 14 743 (26.7) 95 (0.6)
   ≥24 2579 (4.5) 46 (1.8) 15 122 (27.4) 108 (0.7)
   Missing data 955 (1.6) 10 (1.0) 3625 (6.2) 27 (0.7)
Time since first breast cancer diagnosis, yc
   <1 4416 (7.5) 61 (1.4)
   1–2 14 139 (24.0) 144 (1.0)
   3–4 14 085 (23.9) 139 (1.0)
   5–6 10 664 (18.1) 123 (1.2)
   7–9 9681 (16.4) 116 (1.2)
   ≥10 5885 (10.0) 72 (1.2)
Stage of initial breast cancer diagnosisc
   Ductal carcinoma in situ 12 140 (20.6) 197 (1.6)
   Invasive, stage I 29 558 (50.2) 281 (1.0)
   Invasive, stage II 17 172 (29.2) 177 (1.0)
Primary surgeryc
   Breast conserving without radiation 7503 (13.0) 132 (1.8)
   Breast conserving with radiation 29 986 (51.9) 335 (1.1)
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No. (%)
Women (n = 19 078)
With PHBC











Within 1 Year of
Screeningb
   Mastectomy 20 232 (35.1) 157 (0.8)
   Missing data 1149 (2.0) 31 (2.7)
Radiation therapyc
   None 20 872 (36.2) 246 (1.2)
   Any 36 862 (63.8) 380 (1.0)
   Missing data 1136 (1.9) 29 (2.6)
Adjuvant systemic therapyc
   Neither 28 003 (50.6) 363 (1.3)
   Chemotherapy 7765 (14.0) 91 (1.2)
   Endocrine therapy 14 127 (25.5) 103 (0.7)
   Both 5472 (9.9) 47 (0.9)
   Missing data 3503 (6.0) 51 (1.5)
Self-reported history of breast implant, reduction, or reconstructiond
   No 41385 (93.1) 445 (1.1) 48839 (99.2) 259 (0.5)
   Yes 3088 (6.9) 25 (0.8) 380 (0.8) 1 (0.3)
   Missing data 14397 (24.5) 185 (1.3) 9651 (16.4) 82 (0.8)
Abbreviations: BI-RADS, Breast Imaging Reporting and Data System; PHBC, personal history of breast cancer.
a
Percentages were computed after exclusion of missing values.
b
Percentages calculated based on row denominator.
c
Data on first breast cancer diagnosis for PHBC only.
d
Distribution for each variable (by laterality) available from the authors.
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Table 2
Screening Mammography Accuracy and Outcomes in Women With a Personal History of Breast Cancer
(PHBC) and Matched Screening Mammograms in non-PHBC Women
Measure of Accuracy or Outcome








No. of screening mammograms (117 660 screens) [117 740 screens]c 58 830 [58 870]c 58 830 [58 870]c
No. of in situ or invasive breast cancers (956 cancers) [997 cancers]c 615 [655]c 341 [342]c






No. of cancers detected on screening mammography 402 261
CDR/1000 mammograms (117 660 screens) 6.8 (6.2–7.5) 4.4 (3.9–5.0) <.001
   DCIS detection rate (117 660 screens) 2.0 (1.7–2.4) 0.8 (0.6–1.0) <001
   Invasive cancer detection rate (117 660 screens) 4.8 (4.3–5.4) 3.7 (3.2–4.2) .002
CDR/1000 mammograms in PHBC of DCIS (12 135 screens)e 11.5 (9.8–13.6)
CDR/1000 mammograms in PHBC of invasive cancer (46 695 screens)f 5.6 (5.0–6.3)
No. of interval cancers 213 80
ICR/1000 mammograms (117 660 screens) 3.6 (3.2–4.1) 1.4 (1.1–1.7) <.001





Mammograms with additional same-day imaging or recommendation, based on initial











Mammograms positive and recommended for fine-needle aspiration, biopsy, or surgical

































Abbreviations: AIR, abnormal interpretation rate; CDR, cancer detection rate; CI, confidence interval; DCIS, ductal carcinoma in situ; ICR,
interval cancer rate; PPV, positive predictive value.
a
Forty PHBC screens from women with a history of mastectomy, associated with ipsilateral cancer recurrence during followup, were excluded
from analysis of accuracy; all rates are per 1000 screens, and all percentages are shown with numerator and denominator.
b
Forty screens without PHBC (matched screening examinations) were excluded from analysis of accuracy; all rates are per 1000 screens, and all
percentages are shown with numerator and denominator.
c
Numbers and rates in square brackets include 40 screens with ipsilateral cancer (recurrence on mastectomy side), or 40 matched screens in the
cohort without PHBC.
d
Cancer rate refers to all cancers identified in screening participants (screen-detected and interval cancers).
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e
CDR in women with PHBC of DCIS (12135 screens) included DCIS detection rate of 4.9 per 1000 mammograms (95% CI, 3.8–6.3) and invasive
CDR of 6.7 per 1000 mammograms (95% CI, 5.4–8.3).
f
CDR in women with PHBC of invasive cancer (46695 screens) included DCIS detection rate of 1.3 per 1000 mammograms (95% CI, 1.0–1.6) and
invasive CDR of 4.3 per 1000 mammograms (95% CI, 3.8–5.0).
g
Estimates based on positive mammogram results are defined as Breast Imaging Reporting and Data System (BI-RADS) assessments 4 or 5 or a
BI-RADS assessment of 0 or 3 with a recommendation for biopsy, fine-needle aspiration, or surgical consultation. Negative mammogram results
included BI-RADS assessments 1 or 2 or an assessment of 3 without recommendation for biopsy, fine-needle aspiration, or surgical consultation.
Missing final result was BI-RADS assessment of 0 with recommendation for additional imaging or unspecified evaluation or missing
recommendation. All remaining assessments of 0 were considered negative.
h
Percentage of positive mammogram results on final imaging assessment associated with a cancer diagnosis.
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Table 4












Overall screening mammography sensitivity 171/258 66.3 (60.3–71.8) 220/333 66.1 (60.9–70.9)
Age at mammography, y
   <50 34/60 56.7 (44.0–68.5) 18/41 43.9 (29.7–59.2)b
   50–59 47/76 61.8 (50.5–72.0) 43/66 65.2 (53.0–75.6)b
   60–69 36/47 76.6 (62.5–86.5) 52/72 72.2 (61.0–81.2)b
   ≥70 54/75 72.0 (61.0–80.9) 107/154 69.5 (61.9–76.2)b
BI-RADS breast density
   1, Almost entirely fatty 4/5 80.0 (NC)c 7/9 77.8 (NC)c
   2, Scattered fibroglandular tissue 66/93 71.0 (60.8–79.4) 75/108 69.4 (60.2–77.3)
   3, Heterogeneously dense 51/86 59.3 (48.7–69.1) 69/109 63.3 (54.1–71.7)
   4, Extremely dense 11/16 68.8 (43.3–86.4) 10/22 45.5 (26.5–65.9)
Time since last mammogram, mo
   9–14 124/197 62.9 (56.0–69.4) 178/269 66.2 (60.4–71.5)
   15–23 27/37 73.0 (56.7–84.8) 26/38 68.4 (52.2–81.1)
   ≥24 10/13 76.9 (47.8–92.4) 14/23 60.9 (40.2–78.2)
Time since first breast cancer diagnosis, y
   <1 17/22 77.3 (55.6–90.2) 14/24 58.3 (38.3–75.9)b
   1–2 34/57 59.6 (46.5–71.5) 39/66 59.1 (46.9–70.2)b
   3–4 45/69 65.2 (53.3–75.5) 35/64 54.7 (42.6–66.2)b
   5–6 33/43 76.7 (61.9–87.0) 53/70 75.7 (64.4–84.3)b
   7–9 25/42 59.5 (44.6–72.8) 45/67 67.2 (55.3–77.2)b
   ≥10 17/25 68.0 (47.8–83.1) 34/42 81.0 (66.3–90.2)b
Type of first breast cancer
   Ductal carcinoma in situ 83/112 74.1 (65.2–81.4)b 52/72 72.2 (60.8–81.3)
   Invasive cancer 88/146 60.3 (52.1–67.9)b 168/261 64.4 (58.4–69.9)


























   Breast conserving without radiation 55/83 66.3 (55.5–75.6) 29/48 60.4 (46.1–73.1)
   Breast conserving with radiation 99/154 64.3 (56.4–71.5) 108/165 65.5 (57.9–72.3)
   Mastectomy NA NA 75/110 68.2 (59.1–76.1)
Radiation therapy
   None 55/83 66.3 (55.5–75.6) 85/131 64.9 (56.4–72.5)
   Any 99/154 64.3 (56.4–71.5) 128/194 66.0 (59.1–72.2)
Adjuvant systemic therapy
   None 110/153 71.9 (64.3–78.4)b 130/180 72.2 (65.3–78.2)b
   Any, chemotherapy or endocrine 40/78 51.3 (40.2–62.3)b 74/131 56.5 (48.0–64.6)b
Self-reported history of breast implant, reduction, or reconstruction
   No 119/181 65.7 (58.5–72.3) 152/227 67.0 (60.6–72.7)
   Yes 2/3 66.7 (NC)c 7/16 43.8 (22.5–67.6)
Abbreviations: BI-RADS, Breast Imaging Reporting and Data System; CI, confidence interval; NA, not applicable.
a
Numberof screen-detected cancers (ie, positive screen results associated with ipsilateral or contralateral cancer during followup) and total number
of cancers observed at 12mo(ie, number of screens associated with ipsilateral or contralateral cancer during follow-up). For each variable, total in
columns may not equal the overall total because of missing data.
b
P<.05, based on score statistics obtained in generalized estimating equation analyses.
c
Not calculated (NC) if fewer than 10 events
JAMA. Author manuscript; available in PMC 2013 October 19.
